VCNX - Vaccinex Inc Stock Price, Fair Value and News

5.54USD0.00 (0.00%)Delayed

Market Summary

USD5.540.00

Delayed

0.00%

VCNX Stock Price

View Fullscreen

VCNX RSI Chart

VCNX Valuation

Market Cap

8.8M

Price/Earnings (Trailing)

-0.46

Price/Sales (Trailing)

70.78

EV/EBITDA

-0.3

Price/Free Cashflow

-0.52

VCNX Price/Sales (Trailing)

VCNX Profitability

Operating Margin

91.94%

EBT Margin

-15512.10%

Return on Equity

-722.64%

Return on Assets

-260.43%

Free Cashflow Yield

-192%

VCNX Fundamentals

VCNX Revenue

Revenue (TTM)

124.0K

Rev. Growth (Yr)

-81.09%

Rev. Growth (Qtr)

-100%

VCNX Earnings

Earnings (TTM)

-19.2M

Earnings Growth (Yr)

21.46%

Earnings Growth (Qtr)

-17.49%

Breaking Down VCNX Revenue

Last 7 days

-3.6%

Last 30 days

14.5%

Last 90 days

-46.5%

Trailing 12 Months

-93.1%

How does VCNX drawdown profile look like?

VCNX Financial Health

Current Ratio

1.52

Debt/Equity

Debt/Cashflow

-2.8K

VCNX Investor Care

Shares Dilution (1Y)

506.50%

Diluted EPS (TTM)

-26.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	124.0K	0	0	0
2023	825.0K	825.0K	795.0K	570.0K
2022	0	0	100.0K	325.0K
2021	1.5M	1.5M	900.0K	900.0K
2020	0	0	1.1M	1.0M
2019	612.0K	511.0K	717.0K	523.0K
2018	248.5K	407.0K	565.5K	724.0K
2017	0	0	0	90.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vaccinex Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	friedberg albert	bought	1,333	4.73	282	-
Mar 28, 2024	friedberg albert	acquired	799,999	7.77	102,960	-
Mar 28, 2024	zauderer maurice	acquired	300,000	7.77	38,610	president and ceo
Feb 08, 2024	zauderer maurice	acquired	300,000	0.725	413,793	president and ceo
Feb 08, 2024	friedberg albert	acquired	1,200,000	0.725	1,655,170	-
Dec 26, 2023	van strydonck, gerald e.	sold	-2,267	0.72	-3,149	-
Dec 08, 2023	van strydonck, gerald e.	sold	-893	0.67	-1,334	-
Oct 04, 2023	zauderer maurice	bought	4,865	0.973	5,000	president and ceo
Oct 03, 2023	zauderer maurice	bought	4,650	0.93	5,000	president and ceo
Oct 03, 2023	zauderer maurice	bought	500,000	1.00	500,000	president and ceo

Which funds bought or sold VCNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	sold off	-100	-13.00	-	-%
May 15, 2024	Point72 Asset Management, L.P.	new	-	863,606	863,606	-%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-10,743	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	7,743	7,743	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-4,426	-	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	1,074,450	1,074,450	0.01%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-3.00	-	-%
May 15, 2024	MORGAN STANLEY	new	-	8,248	8,248	-%

Are Funds Buying or Selling VCNX?

Are funds buying VCNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VCNX

No. of Funds

Unveiling Vaccinex Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	fcmi parent co.	39.2%	6,405,475	SC 13D/A
Feb 12, 2024	zauderer maurice	14.4%	2,500,771	SC 13D/A
Feb 09, 2024	point72 asset management, l.p.	9.9%	5,793,452	SC 13G
Feb 07, 2024	hirschman orin	9.9%	1,247,061	SC 13G/A
Oct 18, 2023	fcmi parent co.	38.02%	4,750,303	SC 13D/A
Oct 12, 2023	zauderer maurice	11.8%	1,534,324	SC 13D/A
Oct 11, 2023	hirschman orin	9.9%	1,233,382	SC 13G
Sep 26, 2023	zauderer maurice	10.8%	524,324	SC 13D/A
May 25, 2023	fcmi parent co.	40.2%	26,254,537	SC 13D/A
Apr 05, 2023	fcmi parent co.	35.6%	19,542,985	SC 13D/A

Recent SEC filings of Vaccinex Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4/A	Insider Trading
May 14, 2024	4/A	Insider Trading
May 14, 2024	4/A	Insider Trading
May 14, 2024	4/A	Insider Trading

Peers (Alternatives to Vaccinex Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Vaccinex Inc News

Latest updates

Vaccinex Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-	104,000	-	20,000	-	550,000	225,000	50,000	-	50,000	-	850,000	-	625,000	-	404,000	25,000	94,000	194,000	198,000	126,000	206,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	2,000	-	8,000	16,000	175,000	301,000	246,000	246,000	240,000
Costs and Expenses	3.8%	5,178,000	4,988,000	5,854,000	7,077,000	5,536,000	5,344,000	4,842,000	5,518,000	5,113,000	5,669,000	7,090,000	6,089,000	9,208,000	6,339,000	8,082,000	8,883,000	9,234,000	8,755,000	6,652,000	6,683,000	-
S&GA Expenses	-100.0%	-	1,631,000	1,499,000	2,027,000	1,724,000	1,603,000	1,413,000	1,564,000	1,484,000	1,605,000	1,577,000	1,840,000	1,872,000	1,928,000	1,531,000	1,563,000	1,647,000	1,381,000	1,092,000	925,000	1,221,000
R&D Expenses	0.8%	3,383,000	3,357,000	4,355,000	5,050,000	3,812,000	3,741,000	3,429,000	3,954,000	3,629,000	4,064,000	5,513,000	4,249,000	7,334,000	4,411,000	6,543,000	7,304,000	7,412,000	7,073,000	5,314,000	5,512,000	-
EBITDA Margin	-335.4%	-154	-35.40	-27.52	-26.29	-24.22	-60.32	-191	-23.80	-25.37	-17.86	-18.42	-27.26	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	500	-	-	-500	1,000	-16,000	142,000	351,000	332,000	339,000	148,000	-	-	-	-	-	44,000	81,000	267,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-15.8%	-3,897,000	-3,366,000	-4,912,000	-7,060,000	-4,962,000	-5,078,000	-4,759,000	-4,651,000	-5,206,000	-5,969,000	-6,574,000	-6,446,000	-8,754,000	-6,326,000	-7,642,000	-8,828,000	-9,067,000	-8,449,000	-6,599,000	-6,608,000	-
EBT Margin	-335.6%	-155	-35.61	-27.69	-26.50	-24.46	-60.97	-193	-24.89	-26.88	-18.81	-19.17	-28.04	-	-	-	-	-	-	-	-	-
Net Income	-17.5%	-3,897,000	-3,317,000	-4,912,000	-7,060,000	-4,962,000	-5,078,000	-4,759,000	-4,631,000	-5,206,000	-5,969,000	-6,574,000	-6,446,000	-8,754,000	-6,326,000	-7,642,000	-8,828,000	-9,067,000	-8,449,000	-6,599,000	-6,608,000	-
Net Income Margin	-335.5%	-154	-35.53	-27.69	-26.50	-24.46	-60.97	-193	-24.87	-26.88	-18.81	-19.17	-28.04	-	-	-	-	-	-	-	-	-
Free Cashflow	-26.6%	-4,600,000	-3,634,000	-3,118,000	-5,500,000	-5,049,000	-4,597,000	-4,195,000	-5,145,000	-6,069,000	-6,981,000	-7,113,000	-6,346,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	102.9%	7,367	3,631	2,558	3,085	4,895	7,977	8,612	12,572	18,121	9,843	15,189	23,789	30,684	11,702	18,725	3,099	4,881	4,604	10,810	7,121	13,294
Current Assets	113.6%	7,154	3,349	2,206	2,679	4,418	7,478	8,025	12,261	17,766	9,405	14,862	23,442	30,313	11,286	18,237	2,574	4,269	4,010	10,309	6,566	12,750
Cash Equivalents	93.6%	2,972	1,535	127	1,908	3,323	6,391	7,186	11,400	16,803	8,589	13,741	22,385	29,389	10,596	17,092	526	2,491	2,776	8,578	5,279	5,279
Net PPE	-19.1%	110	136	164	177	207	189	236	254	256	297	327	347	371	416	488	525	612	594	501	555	544
Liabilities	-20.7%	4,712	5,942	6,427	3,508	2,495	2,784	2,294	1,629	1,933	2,431	3,299	6,849	7,903	14,314	14,961	8,677	6,620	6,878	6,896	9,501	6,959
Current Liabilities	-20.5%	4,706	5,916	6,362	3,383	2,310	2,537	1,987	1,491	1,777	2,256	2,165	5,715	6,769	13,180	13,827	7,543	-	6,878	-	-	-
Long Term Debt	-76.9%	6.00	26.00	44.00	63.00	82.00	101	119	138	156	175	1,134	1,134	1,134	1,134	1,134	1,134	-	-	-	-	-
LT Debt, Current	1.3%	76.00	75.00	75.00	75.00	75.00	74.00	74.00	74.00	74.00	74.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	26.00	44.00	63.00	82.00	101	119	138	156	175	1,134	1,134	1,134	1,134	1,134	1,134	-	-	-	-	-
Shareholder's Equity	214.9%	2,655	-2,311	-	-	2,400	5,193	6,318	10,943	16,188	7,412	11,890	16,940	22,781	-	3,765	-	-	-	3,914	-	6,335
Retained Earnings	-1.2%	-343,824	-339,900	-336,610	-331,698	-324,638	-319,700	-314,600	-309,800	-304,500	-299,861	-295,200	-290,000	-284,055	-277,481	-271,034	-262,280	-255,779	-248,630	-242,304	-234,662	-225,834
Additional Paid-In Capital	2.3%	345,253	337,627	332,752	331,279	327,044	324,880	320,923	320,789	320,651	307,281	307,128	306,972	284,881	250,914	250,843	232,748	230,086	222,403	222,265	208,329	208,216
Shares Outstanding	38.0%	1,232	893	347	313	261	238	197	194	185	147	147	128	120	107	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	21,963	23,963	23,963	23,963	23,963	23,963	23,963	23,963	23,963
Float	-	-	-	-	10,420	-	-	-	25,255	-	-	-	47,747	-	-	-	23,671	-	-	-	23,013	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-26.6%	-4,600	-3,634	-3,100	-5,500	-5,000	-4,599	-4,146	-5,333	-4,996	-5,145	-6,059	-6,982	-7,114	-6,347	-9,342	-5,448	-7,510	-5,803	-10,490	-5,946	-8,476
Share Based Compensation	-7.7%	96.00	104	115	126	129	132	134	138	141	153	156	128	104	71.00	91.00	366	204	138	137	113	60.00
Cashflow From Investing	-	-	-	-18.00	-	-49.00	2.00	-49.00	-	-	-	-10.00	-	-	1.00	-37.00	-	-254	-	-10.00	2,283	11,800
Cashflow From Financing	21.4%	6,069	5,000	1,332	4,092	2,021	3,802	-19.00	-18.00	13,210	-9.00	-2,575	-	25,907	-115	25,910	3,483	7,479	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VCNX Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 104,000	$ 550,000
Costs and expenses:
Research and development	3,383,000	3,812,000
General and administrative	1,795,000	1,724,000
Total costs and expenses	5,178,000	5,536,000
Loss from operations	(5,074,000)	(4,986,000)
Financing costs - warrant liabilities	(28,000)
Change in fair value of warrant liabilities	1,206,000	0
Other income (expense), net	(1,000)	24,000
Loss before provision for income taxes	(3,897,000)	(4,962,000)
Provision for income taxes	0	0
Net loss attributable to Vaccinex, Inc. common stockholders	(3,897,000)	(4,962,000)
Comprehensive loss	$ (3,897,000)	$ (4,962,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic	$ (2.94)	$ (20.89)
Net loss per share attributable to Vaccinex, Inc. common stockholders, diluted	$ (2.94)	$ (20.89)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic	1,327,257	237,527
Weighted-average shares used in computing net loss per share attributable toVaccinex, Inc. common stockholders, diluted	1,327,257	237,527

VCNX Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,972,000	$ 1,535,000
Accounts receivable	2,775,000	961,000
Prepaid expenses and other current assets	1,312,000	853,000
Derivative asset	95,000
Total current assets	7,154,000	3,349,000
Property and equipment, net	110,000	136,000
Operating lease right-of-use asset	103,000	146,000
TOTAL ASSETS	7,367,000	3,631,000
Current liabilities:
Accounts payable	2,329,000	2,039,000
Accrued expenses	1,880,000	1,242,000
Deferred revenue	59,000	63,000
Current portion of long-term debt	76,000	75,000
Operating lease liability	103,000	146,000
Warrant liability	259,000	2,351,000
Total current liabilities	4,706,000	5,916,000
Long-term debt	6,000	26,000
TOTAL LIABILITIES	4,712,000	5,942,000
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit):
Convertible preferred stock (Series A), par value of $0.001 per share; 10,000,000 shares authorized, 10 shares issued and outstanding as of March 31, 2024, and no shares authorized, issued or outstanding as of December 31, 2023; with aggregate liquidation preference of $1,750,000 and $0 as of March 31, 2024 and December 31, 2023, respectively	1,236,000	0
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of March 31, 2024, and December 31, 2023; 1,584,305 and 892,622 shares issued as of March 31, 2024 and December 31, 2023, respectively;1,584,300 and 892,617 shares outstanding as of March 31, 2024 and December 31, 2023, respectively	1,000	0
Additional paid-in capital	345,253,000	337,627,000
Treasury stock, at cost; 5 shares of common stock as of March 31, 2024 and December 31, 2023, respectively	(11,000)	(11,000)
Accumulated deficit	(343,824,000)	(339,927,000)
TOTAL STOCKHOLDERS' EQUITY/(DEFICIT)	2,655,000	(2,311,000)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 7,367,000	$ 3,631,000

About Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

CEO	Dr. Maurice Zauderer Ph.D.
WEBSITE	vaccinex.com
INDUSTRY	Biotechnology
EMPLOYEES	38

Vaccinex Inc Frequently Asked Questions

What is the ticker symbol for Vaccinex Inc? What does VCNX stand for in stocks?

VCNX is the stock ticker symbol of Vaccinex Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaccinex Inc (VCNX)?

As of Fri May 17 2024, market cap of Vaccinex Inc is 8.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VCNX stock?

You can check VCNX's fair value in chart for subscribers.

What is the fair value of VCNX stock?

You can check VCNX's fair value in chart for subscribers. The fair value of Vaccinex Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaccinex Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VCNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaccinex Inc a good stock to buy?

The fair value guage provides a quick view whether VCNX is over valued or under valued. Whether Vaccinex Inc is cheap or expensive depends on the assumptions which impact Vaccinex Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCNX.

What is Vaccinex Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VCNX's PE ratio (Price to Earnings) is -0.46 and Price to Sales (PS) ratio is 70.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCNX PE ratio will change depending on the future growth rate expectations of investors.